返回排名列表

Align Technology, Inc. (ALGN)

被高估
HealthcareMedical Instruments & SuppliesUnited States

基本面

77

价格

$145.06

市值

$10.35B

第一部分 · 这家公司值多少

概览

Align Technology makes Invisalign, a series of clear, custom-molded plastic trays that gradually straighten teeth as an alternative to metal braces, sold to orthodontists and general dentists who fit and monitor patients through the treatment. It also sells iTero intraoral scanners, which capture a 3D digital model of a patient's mouth used both to plan Invisalign treatment and, more broadly, for other dental and orthodontic work, plus the CAD/CAM software that runs the whole design and manufacturing process.

盈利方式

Align earns Clear Aligner revenue per treatment case: a doctor orders a set of custom aligners, Align manufactures and ships them, and revenue is recognized as trays are delivered over the course of treatment. Systems and Services revenue comes from selling or leasing iTero scanners plus recurring CAD/CAM software and service fees. Because key aligner patents began expiring in 2017, pricing power now rests more on brand recognition, the doctor-training network and scanner ecosystem than on legal exclusivity.

分部营收

Clear Aligner80.43%

Custom clear aligner trays for straightening teeth, sold per treatment case to orthodontists and general dentists worldwide.

Systems and Services19.57%

iTero intraoral scanners plus the CAD/CAM software and services used to plan and manufacture both Invisalign and other dental work.

护城河

品牌 · 狭窄

Invisalign is the name patients ask for by default, built over two decades of marketing and a large trained network of certified doctors. But the aligner patents that once blocked competitors began expiring in 2017, and cheaper rivals plus direct-to-consumer and in-office 3D-printed alternatives have since chipped away at both volume growth and pricing.

需求驱动因素

中度周期性

Straightening teeth is largely elective and often paid out of pocket or through limited dental insurance, so case volumes soften when consumers pull back discretionary spending. Growth also depends on expanding into new international markets and younger teen patients, both of which move independently of any single economic cycle but are still sensitive to household budgets.

主要风险

  • Patent expiry and low-cost competition — Key clear-aligner patents have expired in the US and abroad, letting lower-priced rivals and direct-to-consumer aligner services compete for the same patients and pressure the prices Align can charge.
  • Discretionary consumer spending — Orthodontic treatment is often optional and expensive, so case starts slow when consumers are cautious about spending, even if their teeth alignment need has not changed.
  • International and China exposure — A meaningful part of growth depends on international markets, including China, where local competitors, economic slowdown or regulatory change can reduce case volume independent of trends in the US.
  • Intellectual property litigation — Align is involved in ongoing patent and other IP disputes with competitors and doctors; adverse rulings could restrict product features or require payments that reduce profitability.

客户集中度

Align sells to hundreds of thousands of orthodontic and dental practices worldwide rather than a few large accounts, so no single customer represents a material share of revenue.

看多理由

Buyers argue that Invisalign's brand recognition and trained doctor network still give it the largest share of a clear aligner market that keeps growing as more patients choose aligners over metal braces, with international expansion offering years of additional case growth.

看空理由

Sellers fear that patent expiry has permanently opened the door to cheaper competitors, that elective treatment spending is exposed to consumer caution, and that growth increasingly depends on international markets where Align's brand advantage is weaker.

Written by the editors, published on 2026年8月18日

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年8月23日 with claude-opus-5 — shared with all users

P/E: 40.5Score: 59Market cap: $3.87B

Its Ormco unit sells the Spark clear aligner system to the same orthodontists Invisalign is sold to, competing case by case on aligner material, software and treatment planning.

P/E: —Score: 55Market cap: $1.90B

Sells SureSmile clear aligners and Primescan intraoral scanners to the same dental practices, overlapping with both of Align's businesses at once.

P/E: 10.8Score: 67Market cap: $15.24B

Its Dental Solutions arm sells Clarity aligners, brackets and bonding systems to orthodontists, competing for the same orthodontic case volume.

Straumann Holding AGSTMN

Its ClearCorrect aligner brand competes for the same orthodontic and general-dentist customers worldwide, pushed through Straumann's large European implant and digital-dentistry sales network.

Angelalign Technology Inc. (时代天使)6699

The largest clear aligner maker in China and now expanding into Europe, Latin America and Asia, taking aligner cases directly from Invisalign in the markets Align counts on for growth.

3Shape A/SNot tracked

Its TRIOS intraoral scanners are the main alternative to Align's iTero scanners in dental practices, competing for the chairside digital-scanning workflow.

资产负债表与流动性

营收

$4.14B

最近12个月(截至2026/6/30)

净利润

$414M

最近12个月(截至2026/6/30)

自由现金流

$491M

股东权益合计

$4.05B

负债合计

$2.18B

流动比率

1.40

利息覆盖率

-

债务/EBITDA

0.15

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被高估

公允价值

$118.35

当前价格

$145.06

安全边际

-22.6%

公允价值区间

$76.93 - $159.77

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$208.60
现金流折现法(DCF):$94.10
市盈率法(P/E):$72.43
格雷厄姆成长公式:$43.08
盈利能力价值(EPV):$43.10
合理市净率(P/B):$37.33
股息折现模型(戈登模型):数据不足,无法计算
P/FFO(运营资金):$145.90
周期中段收益:$206.75
市销率法(P/S):$228.04
分析师共识:买入 (16B / 8H / 1S)
最近财报超预期:-0.87%

估值指标

市盈率(P/E)

25.32

ROE

10.1%

市净率(P/B)

2.44

P/FCF

16.30

毛利率

68.0%

ROIC

9.6%

盈利能力雷达图

价值创造(经济护城河)

ROIC

9.6%

WACC

13.9%

ROIC − WACC

-4.3 pp

ROIC 低于资本成本:公司每投入一美元都在毁灭价值。

基本面分析标准

通过(21)

  • EPS shows upward trend
  • EPS CAGR 9.65%
  • ROIC 9.6%
  • Gross Margin 68.0%
  • P/FCF 16.30
  • P/B Ratio 2.44
  • Debt/Equity ratio
  • Operating Margin 13.2%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 10.1%
  • Revenue Growth 5Y 10.3%
  • Analyst Consensus 64% Buy
  • Earnings Surprise avg 6.3%
  • Earnings Quality (OCF/NI) 1.83
  • Share Dilution -3.1%
  • Piotroski F-Score 7/9

未通过(4)

  • Price CAGR 4.42%
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Net Margin Trend 10.0% vs 11.0%

不可用(3)

  • Dividend Payout NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-评分

7/9

财务状况强健

score
criteria

盈利质量

1.83

高质量:盈利有现金流支撑

股权稀释

-3.1%

正在回购股份,对股东友好

机构持股

公司治理

管理团队

姓名职位年龄
Mr. Joseph M. HoganPresident, CEO & Director68
Mr. John F. MoriciCFO & Executive VP of Global Finance58
Mr. Zelko RelicExecutive VP & CTO60
Ms. Shirley StacyVice President of Corporate Communications & Investor Relations-
Richardson Jaime HolteExecutive Vice President of Global Human Resources-
Ms. Sreelakshmi KolliExecutive VP and Chief Product & Digital Officer50
Mr. Srini KazaExecutive Vice President of Research & Development-
Dr. Mitra DerakhshanExecutive VP, Chief Clinical Officer, Global Treatment Planning & Clinical Services-
Mr. David CarrExecutive VP and MD of EMEA-
Mr. Frank QuinnExecutive VP & MD of Americas Region-

审计风险

1

董事会风险

4

薪酬风险

9

股东权利风险

7

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-02-27

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-08-05

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-08-31

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for ALGN, sourced from Markets Gazette.

  • 4/7/2026POSITIVE
    Alignment Stock Surges After 2.48% Medicare Rate Hike

    Alignment Healthcare Inc. experienced a significant surge in its stock price following the Centers for Medicare & Medicaid Services (CMS) announcement of a 2.48% rate increase for 2027 Medicare Advantage and Part D programs. This favorable adjustment is expected to bolster the company's revenue streams and profitability, as these programs represent a substantial portion of Alignment Healthcare's business. Investors are reacting positively to the improved financial outlook, anticipating enhanced earnings and a stronger market position for the healthcare provider.

  • 3/19/2026POSITIVE
    Align Technology Shares Jump Following Report Of Large Elliott Position

    Align Technology shares surged following news that activist investor Elliott Investment Management has taken a significant stake in the company. Elliott's involvement typically signals a push for strategic changes, often aimed at unlocking shareholder value. The move comes as Align Technology, the maker of Invisalign, faces challenges in its post-pandemic growth trajectory. Investors are likely interpreting this as a potential catalyst for operational improvements and a re-evaluation of the company's strategic direction, which could lead to enhanced financial performance.

  • 3/19/2026NEUTRAL
    Elliott Builds Stake in Invisalign-Maker Align Technology

    Hedge fund Elliott Investment Management has acquired a substantial stake in Align Technology Inc., the company renowned for its Invisalign clear aligners. This move by a prominent activist investor suggests potential for strategic changes or operational improvements within Align Technology. While the specific intentions of Elliott are not yet disclosed, such stake-building often precedes engagement with management to unlock shareholder value. Investors will be watching closely for any strategic shifts or performance enhancements that Elliott may advocate for, which could impact the company's future trajectory and stock performance.

via Markets Gazette